Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Fresh Meadows, New York Clinical Trials

A listing of Fresh Meadows, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (128) clinical trials

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). Approximately ...

Phase

0.7 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

1.53 miles

Learn More »

Study of Anxiety in African American Men With Prostate Cancer

OBJECTIVES: Primary - To establish the psychometric properties of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) in African American men with prostate cancer. - To establish the reliability of the MAX-PC in African American men with prostate cancer. - To establish the validity of the MAX-PC in African American ...

Phase N/A

1.76 miles

Learn More »

People with prostate cancer are asked to participate in a research study being conducted by Queens Hospital Center.

Phase N/A

1.76 miles

Learn More »

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

This study is a multicenter, randomized, double-blind, placebo controlled, dose finding study of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT. The study will have four arms with 30 subjects per arm. The subjects participating in the study will have advanced prostate cancer ...

Phase

5.47 miles

Learn More »

Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in patients undergoing active surveillance for localized prostate cancer. ProstAtak involves the use of aglatimagene besadenovec (AdV-tk) to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the ...

Phase

5.47 miles

Learn More »

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

Phase

5.47 miles

Learn More »

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Phase

5.47 miles

Learn More »

A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Phase N/A

5.47 miles

Learn More »

Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to ...

Phase

5.47 miles

Learn More »